# US 2014/0155442 A1 · Anti-obesity agent comprising high-purity epa > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0155442 A1 - Document ID: US20140155442A1 - Status: Published application - Kind: A1 - Application number: 14/129,890 - Filed: 2012-07-06 - Published: 2014-06-05 - Earliest claimed: 2011-07-07 - Assignees: Mochida Pharmaceutical Co., Ltd. - Inventors: Takayuki Ishida; Hiroyuki Kawano - Web page: https://patentgrep.com/patent/US20140155442A1 ## CPC - A61K 31/232: having three or more double bonds, e.g. etretinate - A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol - A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557) - A61K 31/421: 1,3-Oxazoles, e.g. pemoline, trimethadione - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 3/04: Anorexiants; Antiobesity agents - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention provides an agent for preventing the increase in a body weight (or for decreasing a body weight) or an anti-obesity agent each comprising at least one component selected from the group consisting of EPA and pharmaceutically acceptable salts, esters and derivatives thereof as an active ingredient for obesity in which the increase in the formation of hepatic lipid or the occurrence of fatty liver is mild, preferably the increase in the formation of hepatic lipid or the occurrence of fatty liver is not observed. ## Claims ### Claim at position 1 -8. (canceled) ### Claim 9 A method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity comprising the step of administering an agent for suppressing body weight gain (for reducing body weight) or an anti-obesity agent containing at least one member selected from EPA and pharmaceutically acceptable salts, esters, and derivatives thereof as its effective component to a patient suffering from obesity, and in particular, obesity of a type wherein enhancement of hepatic lipogenesis or fatty liver is mild or preferably not recognized. ### Claim 10 (depends on 9) The method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity according to claim 9, wherein the effective component is EPA-E. ### Claim 11 (depends on 9) The method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity according to claim 9, wherein purity of the effective component is as high as 90% by weight or more. ### Claim 12 (depends on 9) The method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity according to claim 9, wherein the effective component is administered at a dose effective for suppressing increase of CETP activity and/or LDL-C level. ### Claim 13 (depends on 9) The method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity according to claim 9, wherein the agent is substantially free from DHA or pharmaceutically acceptable salts, esters, and derivatives thereof. ### Claim 14 (depends on 9) The method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity according to claim 9, wherein the obesity is induced by intake of high fat diet, and in particular, induced by continuous intake of high fat diet. ### Claim 15 (depends on 9) The method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity according to claim 9, comprising the step of administering a blended drug containing at least one member selected from EPA and pharmaceutically acceptable salts, esters, and derivatives thereof as its first effective component and at least one CETP inhibitor as its second effective component. ### Claim 16 (depends on 9) The method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity according to claim 9, wherein the CETP inhibitor is dalcetrapib or anacetrapib. ### Claim 17 (depends on 10) The method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity according to claim 10, wherein purity of the effective component is as high as 90% by weight or more. ### Claim 18 (depends on 10) The method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity according to claim 10, wherein the effective component is administered at a dose effective for suppressing increase of CETP activity and/or LDL-C level. ### Claim 19 (depends on 10) The method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity according to claim 10, wherein the agent is substantially free from DHA or pharmaceutically acceptable salts, esters, and derivatives thereof. ### Claim 20 (depends on 10) The method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity according to claim 10, wherein the obesity is induced by intake of high fat diet, and in particular, induced by continuous intake of high fat diet. ### Claim 21 (depends on 10) The method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity according to claim 10, comprising the step of administering a blended drug containing at least one member selected from EPA and pharmaceutically acceptable salts, esters, and derivatives thereof as its first effective component and at least one CETP inhibitor as its second effective component. ### Claim 22 (depends on 10) The method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity according to claim 10, wherein the CETP inhibitor is dalcetrapib or anacetrapib. ### Claim 23 A method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity, comprising the step of administering an agent for suppressing body weight gain (for reducing body weight) or an anti-obesity agent containing at least one member selected from EPA and pharmaceutically acceptable salts, esters, and derivatives thereof as its effective component, for combined administration with at least one compound selected from CETP inhibitors which is a second effective component. ### Claim 24 (depends on 23) The method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity according to claim 23, comprising the step of administering a blended drug containing at least one member selected from EPA and pharmaceutically acceptable salts, esters, and derivatives thereof as its first effective component and at least one CETP inhibitor as its second effective component. ### Claim 25 (depends on 23) The method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity according to claim 23, wherein the CETP inhibitor is dalcetrapib or anacetrapib. ### Claim 26 (depends on 24) The method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity according to claim 24, wherein the CETP inhibitor is dalcetrapib or anacetrapib.